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variables (age, marital status, education, employment, income,
comorbidity), older age, widowhood, lower education, retire-
ment, and comorbidity (Charlson > 2), were associated with
lower QoL (all p < 0.05). In multivariate analyses, all patient-
related variables explained 18–21% of the variance in scores.
With the addition of disease-related variables (treatment with
radical prostatectomy, radiation, or hormones; metastases,
Gleason score at diagnosis), the model explained 21–25% of the
variance. Patients currently on hormone treatment had lower
PORPUS-Ui and HUI3 scores than patients treated with hor-
mones in the past or never (p < 0.05). System-related variables
(year and county of diagnosis) contributed little to the explained
variance (1–3%). Symptom-related variables (PCI urinary,
sexual, bowel function) were the strongest predictors of QOL
(explaining 47–70% of the variance). CONCLUSION: Symp-
toms related to PC and its treatment have large effects on the
QoL of PC survivors. Although many variables are associated
with QoL, only prostate symptoms and comorbidity have inde-
pendent effects.
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OBJECTIVE: A multicenter phase III trial showed patients with
stage III or IV follicular lymphoma who achieved a partial or
complete remission after ﬁrst-line treatment receiving 90Y-
ibritumomab tiuxetan had signiﬁcantly longer PFS time as com-
pared to similar patients receiving no treatment. The objective of
this study was to determine the impact of 90Y-ibritumomab
tiuxetan on health-related quality of life. METHODS: Health-
related quality of life was assessed using EORTC QLQ-C30
version 2 and EuroQoL-5D (EQ-5D) questionnaires. These ques-
tionnaires were administered at screening, week 14 and every 6
months thereafter and ﬁnally at end of follow-up. Descriptive
statistics were used to compare scores across treatment groups.
The change in scores from baseline was also assessed by gender,
age and ﬁrst-line treatment. Mixed effects model was used to
assess the factors that were associated with ﬁnal scores of Visual
Analogue Scale (VAS) of EQ-5D.RESULTS:Nonotable treatment
differences were observed in the scores of EORTC QLQ-C30 (all
domains) scores across timepoints or changes from baseline. This
result was true for all sub-groups. The mean scores for EQ-5D at
screening and ﬁnal visit were 0.83 and 0.84 for 90Y-ibritumomab
tiuxetan and 0.84 and 0.83 for control arm. The mean VAS scores
at screening and ﬁnal visit were 77.52 and 77.64 for 90Y-
ibritumomab tiuxetan and 76.57 and 78.51 for control arm. An
analysis of factors associated with ﬁnal VAS scores showed that
baseline VAS scores affected ﬁnal VAS scores (p < 0.0001). CON-
CLUSION: There appears to be no difference in quality of life for
patients on 90Y-ibritumomab tiuxetan as compared to those in
control arm as measured by EORTC QLQ C-30 and EQ-5D
questionnaires. 90Y-ibritumomab tiuxetan prolongs PFS without
impacting the health-related quality of life of patients.
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OBJECTIVE: To quantify the impact of disease and its treatment
on patient-reported well-being, it is important to consider the
patient’s economic circumstances. This study explored the rela-
tionship between annual household income and health-related
psychological well-being among insured, long-term (>ﬁve years)
colorectal cancer (CRC) survivors with and without permanent
intestinal stomas. METHODS: This is a secondary analysis of
data collected as part of an NCI-funded study of health-related
quality of life (HRQOL) among CRC survivors, in which 681
respondents (52% response rate) completed a survey instrument
that included the modiﬁed City of Hope Quality of Life (mCOH-
QOL)–Ostomy questionnaire, SF-36 v2, and socio-demographic
items. Of these, 588 subjects provided income data and were
included in this analysis. The mCOH-QOL–Ostomy is based on
a four-dimension model of HRQOL (physical, psychological,
social, and spiritual well-being). For this analysis, the dependent
variable was the psychological well-being (PWB) score. Hierar-
chical linear regression was used to explore the unique contribu-
tion of income to the total variance of PWB over and above the
model that included the following independent variables: self-
reported physical health (SF-36v2 PCS), co-morbidity (Charlson-
Deyo), age, sex, race/ethnicity, education, partnered status, and
presence of an ostomy. RESULTS: After accounting for the pro-
portion of variance in PWB explained by the other independent
variables, the additional variance explained by income was sig-
niﬁcant (R2 increased from 0.228 to 0.250; p = 0.006). When
compared to those in the highest household income category
(>$100,000), subjects in the lowest income category (<$5000)
had a clinically meaningful 0.82 point lower PWB score on the
11-point scale. Signiﬁcant positive predictors of PWB were PCS
score, age, and absence of an ostomy. CONCLUSION: Although
the study design does not allow causal inference, these results
demonstrate a signiﬁcant relationship between income and PWB
that merits further consideration when attempting to interpret
patient-reported outcomes, particularly HRQOL.
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OBJECTIVE: To provide qualitative data on the men’s experi-
ence, impact and relative importance of hot ﬂushes as a result of
prostate cancer therapies, with an emphasis on gonadotropin-
releasing hormone (GnRH) agonists. METHODS: A qualitative
study applying a non-probabilistic purposive sampling strategy.
Participants were over 50 years old with histologically conﬁrmed
adenocarcinoma of the prostate, had recently initiated (6
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